TMED2

TMED2 (p24A/p24β1) is a type I transmembrane p24-family cargo receptor that operates in the early secretory pathway, cycling between the ER, intermediate compartment, and cis-Golgi via large microtubule-dependent pre-Golgi carriers in a G-protein-dependent manner (PMID:8663407, PMID:9914165). It functions as a hetero-oligomer whose integrity it controls: loss of TMED2 in vivo concurrently destabilizes its partners TMED7 and TMED10, and TMED2 is required for mouse embryo morphogenesis and placental labyrinth formation (PMID:20178780). Through its N-terminal GOLD domain, TMED2 binds the second extracellular loop of client receptors—engaging acidic residues in the extracellular loops of multiple GPCRs (PAR-1, PAR-2, P2Y receptors, μ-opioid receptor)—and then releases them in an ARF1-dependent manner to permit anterograde trafficking, so that dominant-negative GOLD fragments arrest cargo at intracellular compartments and block receptor resensitization (PMID:17693410, PMID:21219331). This receptor-chaperoning role extends to the calcium-sensing receptor, whose immature ER form it stabilizes and routes to the plasma membrane (PMID:20361938), to Toll-like receptors TLR2/3/4 whose ER-to-Golgi export it mediates (PMID:37491993), and to Fibronectin, which is retained in the ER upon TMED2 loss (PMID:30236446). TMED2 also acts as a negative regulator of trafficking for Smoothened, retaining SMO in the ER and Golgi to repress Hedgehog signaling strength during neural differentiation (PMID:35353806). Beyond discrete cargo handling, TMED2 together with TMED10 forms a supercomplex that exchanges cholesterol and ceramides at ER-Golgi membrane contact sites, controlling plasma membrane lipid nanodomain composition (PMID:36174556), and upon viral infection it associates with MITA/STING to reinforce its dimerization and ER-to-vesicle trafficking required for type I interferon production (PMID:30540941).

1. 1996 Medium

   Established TMED2 as a p24-family transmembrane protein of the secretory pathway, framing it as a candidate vesicular transport factor rather than an uncharacterized membrane protein.

   Evidence Protein isolation, cloning, sequence analysis, and subcellular fractionation identifying a KKXX ER retrieval motif and homology to yeast Emp24p

   PMID:8663407

   Open questions at the time

   • No direct cargo identified
   • Functional role in transport inferred from homology, not demonstrated
2. 1999 High

   Defined how and where TMED2 moves, showing it continuously cycles between the intermediate compartment and cis-Golgi on microtubule-dependent carriers under G-protein control.

   Evidence GFP-fusion live imaging, FRAP, and AlF4- pharmacological perturbation in cultured cells

   PMID:9914165

   Open questions at the time

   • Identity of the regulating G-protein not resolved
   • Cargo carried during cycling not defined
3. 2007 High

   Provided the first mechanistic cargo model, demonstrating GOLD-domain binding to a receptor extracellular loop and ARF1-dependent release as the basis for regulated anterograde trafficking.

   Evidence Reciprocal co-IP, GOLD domain-mapping mutagenesis, ARF1 perturbation, and PAR-2 resensitization assays

   PMID:17693410

   Open questions at the time

   • Mechanism of ARF1-triggered release not structurally resolved
   • Generality across receptor classes not yet tested
4. 2010 Medium

   Extended the cargo-chaperone role to receptor biogenesis, showing TMED2 stabilizes the immature ER form of CaSR and promotes its plasma membrane delivery.

   Evidence Yeast two-hybrid, co-IP, glycosylation analysis, and mutant plasma membrane expression assays in HEK293 cells

   PMID:20361938

   Open questions at the time

   • FF/AA motif role in release not mechanistically explained
   • Single-lab interaction data
5. 2010 High

   Demonstrated in vivo that TMED2 maintains the protein levels of its hetero-oligomeric partners and is essential for embryonic and placental morphogenesis, establishing functional interdependence of the p24 complex.

   Evidence ENU point-mutant mice, Western blotting, immunofluorescence, and mutant embryo analysis

   PMID:20178780

   Open questions at the time

   • Cargo responsible for morphogenesis defects not identified at this stage
   • Mechanism linking complex loss to placental failure unresolved
6. 2011 Medium

   Generalized the GOLD-domain receptor interaction to a broad GPCR clientele, identifying acidic extracellular-loop residues as the shared recognition determinant.

   Evidence Co-IP with multiple GPCRs, dominant-negative fragment overexpression, and trafficking assays in HEK293 cells and primary astrocytes

   PMID:21219331

   Open questions at the time

   • Selectivity rules among receptors not defined
   • Quantitative binding affinities not measured
7. 2018 High

   Revealed a stimulus-specific signaling role, showing TMED2 is recruited to MITA/STING upon viral infection to reinforce dimerization and trafficking needed for type I IFN responses.

   Evidence Stimulus-dependent co-IP, TMED2 knockdown/knockout, IFN and viral load assays, and MITA dimerization/trafficking readouts

   PMID:30540941

   Open questions at the time

   • How viral stimulus triggers the TMED2-MITA association is unknown
   • Whether the p24 complex partners participate not addressed
8. 2018 Medium

   Connected the in vivo morphogenesis phenotype to a specific cargo by identifying Fibronectin as ER-retained upon TMED2 loss in the chorion.

   Evidence Tissue-specific genetic analysis, ex vivo chorion-allantois recombination, and Fibronectin ER-retention immunostaining

   PMID:30236446

   Open questions at the time

   • Direct TMED2-Fibronectin binding not shown
   • Whether other cargo contribute to the defect unresolved
9. 2022 High

   Uncovered a lipid-transfer function distinct from cargo handling, placing TMED2 with TMED10 in a supercomplex that exchanges cholesterol and ceramides at ER-Golgi contact sites to shape plasma membrane nanodomains.

   Evidence Anthrax-toxin genetic screen, biochemical fractionation, lipid composition analysis, and KO cell lines

   PMID:36174556

   Open questions at the time

   • Direct lipid-transfer activity of TMED2 vs. scaffolding role not distinguished
   • Structure of the supercomplex unknown
10. 2022 High

    Established TMED2 as a negative trafficking regulator, retaining Smoothened in the ER/Golgi to dampen Hedgehog signaling during neural differentiation.

    Evidence Haploid ESC genetic screen, super-resolution microscopy, binding assay, and neural differentiation assays

    PMID:35353806

    Open questions at the time

    • Mechanism of SMO release under Hedgehog stimulation not defined
    • Whether retention uses the GOLD domain not tested here
11. 2023 Medium

    Broadened the cargo repertoire to innate immune receptors, showing TMED2 mediates ER-to-Golgi export of TLR2/3/4.

    Evidence Co-IP/pulldown, dominant-negative constructs, and trafficking assays

    PMID:37491993

    Open questions at the time

    • Recognition motif on TLRs not mapped
    • Selectivity excluding TLR5/TLR9 not mechanistically explained
12. 2023 Low

    Proposed a disease-associated role in which TMED2 supports cisplatin resistance by promoting KEAP1 ubiquitination and relieving inhibition of Nrf2.

    Evidence Overexpression/knockdown in breast cancer lines, ubiquitination assay, and viability/apoptosis readouts

    PMID:37615927

    Open questions at the time

    • Western-blot-based mechanistic inference without reconstitution or structural validation
    • Direct TMED2-KEAP1 interaction not established
    • Link to TMED2's trafficking function unclear
13. 2024 Low

    Suggested a recycling role beyond anterograde transport, with TMED2 promoting EGFR return to the plasma membrane to enhance EGFR-AKT signaling in glioma.

    Evidence Knockdown/overexpression in glioma lines, recycling and AKT readouts, and xenograft model

    PMID:38354922

    Open questions at the time

    • Recycling mechanism not biochemically reconstituted
    • Direct EGFR engagement not demonstrated
    • Single-lab study
14. 2025 Low

    Implicated TMED2 in tumor progression via MAPK/MEK/ERK activation with CKAP4 as a downstream effector in osteosarcoma.

    Evidence shRNA knockdown, Western blotting, xenograft model, and CKAP4 epistasis

    PMID:42165997

    Open questions at the time

    • Downstream effector identified by co-knockdown without direct interaction validation
    • Connection to TMED2 trafficking activity not established

• How a single GOLD-domain receptor selects among its diverse cargo and switches between promoting versus restraining their surface delivery remains unresolved.
• No structural model of GOLD-cargo recognition
• Rules distinguishing anterograde export from ER retention not defined
• Mechanistic basis of stimulus-dependent partner selection (e.g. STING) unknown